DRG Market Assessment reports

Triple-negative breast cancer is an aggressive disease with high unmet need. There has been a historical lack of targeted therapies, although the treatment landscape has evolved with the approval…

The gastroesophageal cancer market (including gastric, gastroesophageal junction, and esophageal cancer) is witnessing a substantial change, largely fueled by the entry of immune checkpoint…

The current treatment armamentarium for non-small-cell lung cancer (NSCLC) is dominated by biomarker-driven therapies and immune checkpoint inhibitors. Therapeutic options in this indication have…

Disease stage, primary tumor resectability, and BRAF mutation status are key parameters influencing the treatment paradigm of malignant melanoma patients. BRAF/MEK inhibitor combination regimens,…

Metastatic non-small-cell lung cancer (NSCLC) is a highly segmented indication defined by tumor histology and mutational status. Metastatic nonsquamous NSCLC patients are routinely tested for the…

Metastatic non-small-cell lung cancer (NSCLC) is a highly segmented indication defined by tumor histology and mutational status. Metastatic nonsquamous NSCLC patients are routinely tested for the…

Since the approval of immune checkpoint inhibitors, the treatment of bladder cancer has been transformed. Keytruda (Merck & Co.) and Opdivo (Bristol Myers Squibb) are now options in earlier…

Hepatocellular carcinoma, the most common type of liver cancer, occurs as a result of chronic liver cirrhosis. It has a five-year survival rate of only 18%. First-line advanced hepatocellular…

Hepatocellular carcinoma, the most common type of liver cancer, occurs as a result of chronic liver cirrhosis. It has a five-year survival rate of only 18%. First-line advanced hepatocellular…

Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need, remains a key area of focus for drug developers. NSCLC is defined by driver mutations, and treatment is…

The introduction of immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy (Bristol Myers Squibb), and Tecentriq (Roche / Genentech; United States only), as well as BRAF/MEK …

Chemotherapy and hormonal therapy have been the mainstay treatments of advanced endometrial carcinoma, but treatment is becoming more directed, as a result of tumor analysis. Immune checkpoint…